Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 1

Interventions

pembrolizumab 77Cyclophosphamide 50Cisplatin 47Nivolumab 37Paclitaxel 34Radiotherapy 33Carboplatin 32Gemcitabine 29Docetaxel 27Dexamethasone 24atezolizumab 23Doxorubicin 21Bevacizumab 21Etoposide 20Blood Specimen Collection 20Magnetic Resonance Spectroscopy 19Vincristine 18Radiosurgery 18Leucovorin 18Lenalidomide 18Fluorouracil 18fludarabine 17Rituximab 17Oxaliplatin 16Ipilimumab 16Cytarabine 16palbociclib 15Surveys and Questionnaires 15Radiation 15Letrozole 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × azeliragon × 90 days × Clear all
NCT05635734 2026-05-29

Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Cantex Pharmaceuticals

Phase 1/2 Completed
33 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡